Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | WHR1 | P49842 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22096980 | 0.96 | MEN1 (0.47) | MEN1KMT2AATMWHR1NUDT1 | |
| SCHEMBL23156650 | 0.91 | ATM (0.44) | MEN1KMT2AATMWHR1NUDT1 | |
| SCHEMBL13877443 | 0.90 | ATM (0.55) | MEN1KMT2AATMWHR1NUDT1 | |
| SCHEMBL13877447 | 0.90 | MEN1 (0.55) | MEN1KMT2AATMWHR1NUDT1 | |
| SCHEMBL17206507 | 0.88 | MEN1 (0.51) | MEN1KMT2AATMWHR1NUDT1 | |
| SCHEMBL17206501 | 0.88 | MEN1 (0.45) | MEN1KMT2AATMWHR1NUDT1 | |
| SCHEMBL21031671 | 0.87 | MEN1 (0.41) | MEN1KMT2AATMWHR1NUDT1 | |
| SCHEMBL21030867 | 0.87 | MEN1 (0.41) | MEN1KMT2AATMWHR1NUDT1 | |
| SCHEMBL22096993 | 0.87 | KDM4E (0.41) | MEN1KMT2AATMHPGDKDM4E | |
| SCHEMBL22097099 | 0.87 | KDM4E (0.41) | MEN1KMT2AATMHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236075-B2 | Organic compound and organic electroluminescence device using the same | LUMINESCENCE TECHNOLOGY CORP. (TW) | 2022-02-01 | — | — | US | disclosed |
| US-20200190065-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | LUMINESCENCE TECHNOLOGY CORPORATION (TW) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236075-B2 | Organic compound and organic electroluminescence device using the same | ICMT, OR10J3, PIEZO1 | MEN1 1207/4885KMT2A 2500/4885ATM 3884/4885 |
| US-20200190065-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | ICMT, OR10J3, PIEZO1 | MEN1 1207/4885KMT2A 2500/4885ATM 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.